Holen Sie sich die Stockscreener-App
9.79
3.71%
0.35
Schlusskurs vom Vortag:
$9.44
Offen:
$9.34
24-Stunden-Volumen:
165.79K
Relative Volume:
3.13
Marktkapitalisierung:
$203.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-28.50M
KGV:
-5.4005
EPS:
-1.8128
Netto-Cashflow:
$-25.87M
1W Leistung:
+31.94%
1M Leistung:
+66.50%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.34
$10.00
1-Wochen-Bereich:
$7.32
$10.00
52-Wochen-Spanne:
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Firmenname
Satellos Bioscience Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
9.79 | 203.94M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-06 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Aktie (MSLE) Neueste Nachrichten
Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win - Streetwise Reports
Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data By Investing.com - Investing.com India
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data - Investing.com South Africa
Satellos reports six-month Phase II data for SAT-3247 in Duchenne muscular dystrophy - The Pharma Letter
HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock - MarketBeat
MSLE Maintained by HC Wainwright & Co. -- Price Target Raised to $18.00 - GuruFocus
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - Investing News Network
Phase II DMD Trailhead data hike Satellos’ stock - BioWorld News
Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD - Moomoo
Satellos reports positive TRAILHEAD data for DMD drug - grafa.com
Why Is Satellos Bioscience Trading Higher Today?Satellos Bioscience (NASDAQ:MSLE) - Benzinga
Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients - TipRanks
[6-K] Satellos Bioscience Inc. Current Report (Foreign Issuer) | MSLE SEC FilingForm 6-K - Stock Titan
Satellos Reports Six-Month Interim TRAILHEAD Data Showing - GlobeNewswire
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence - Sahm
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
If You Invested $1,000 in Satellos Bioscience Inc (MSCLF) - Stock Titan
Why Satellos Bioscience Inc. stock is rising today - Wealth Awesome
Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market - Streetwise Reports
Why Satellos Bioscience Inc. stock is plummeting today - Wealth Awesome
Satellos Bioscience Ord Shs (MSLE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Guggenheim Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Satellos gets FDA Fast Track for SAT-3247 - grafa.com
Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation - marketscreener.com
Stocks in play: Satellos Bioscience Inc. - The Globe and Mail
Satellos Bioscience Shares Climb After FDA Fast Track Designation - Moomoo
Fast Track Designation for Satellos' SAT-3247 (MSLE) in Duchenne Treatment - GuruFocus
Satellos Wins FDA Fast Track Status for Duchenne Drug SAT-3247 - TipRanks
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program - Stock Titan
Satellos wins FDA Fast Track for Duchenne drug SAT-3247 - Stock Titan
Price to sales forward of Satellos Bioscience Inc – TSX:MSCL - TradingView
Satellos Bioscience Inc Actuals & Estimates (DUS:0IT) - TradingView
Price to earnings forward of Satellos Bioscience Inc – TSX:MSCL - TradingView
EBITDA margin % of Satellos Bioscience Inc – DUS:0IT - TradingView
Price to earnings forward of Satellos Bioscience Inc – DUS:0IT - TradingView
Enterprise value to revenue forward of Satellos Bioscience Inc – DUS:0IT - TradingView
Operating margin % of Satellos Bioscience Inc – DUS:0IT - TradingView
Satellos Bioscience Inc Statistics – DUS:0IT - TradingView
0IT Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Price to book forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Price to earnings forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Enterprise value to EBIT forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Satellos Bioscience Inc Actuals & Estimates (TSX:MSCL) - TradingView
Satellos Bioscience Inc Actuals & Estimates (FWB:0IT) - TradingView
Satellos to Present Clinical Program Updates at ICNMD 2026 - Investing News Network
Finanzdaten der Satellos Bioscience Inc-Aktie (MSLE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):